Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5237309 | 0.86 | KDM4E (0.58) | MAPK1KDM4EHIF1AMTNR1AMTNR1B | |
| SCHEMBL13921582 | 0.85 | ALDH1A1 (0.46) | MAPK1KDM4EALDH1A1TSHRMEN1 | |
| SCHEMBL11441088 | 0.84 | KDM4E (0.62) | MAPK1KDM4EHIF1AALDH1A1PAOX | |
| SCHEMBL11064976 | 0.83 | ALDH1A1 (0.46) | MAPK1KDM4EMTNR1AMTNR1BALDH1A1 | |
| SCHEMBL11064973 | 0.83 | ALDH1A1 (0.44) | MAPK1KDM4EALDH1A1TSHRMEN1 | |
| SCHEMBL9853199 | 0.83 | MTNR1A (0.50) | MAPK1KDM4EHIF1AMTNR1AMTNR1B | |
| SCHEMBL9491670 | 0.82 | KDM4E (0.67) | MAPK1KDM4EHIF1AALDH1A1PAOX | |
| SCHEMBL7445070 | 0.82 | KDM4E (0.67) | MAPK1KDM4EHIF1AALDH1A1PAOX | |
| SCHEMBL29315300 | 0.82 | KDM4E (0.67) | MAPK1KDM4EHIF1AALDH1A1PAOX | |
| SCHEMBL17124613 | 0.81 | ALDH1A1 (0.43) | MAPK1KDM4EALDH1A1TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100163070-A1 | METHOD FOR STRAIGHTENING KERATINOUS FIBRES USING HEATING MEANS AND AN AMIDE | L'OREAL S.A. (FR) | 2010-07-01 | — | — | US | claimed |
| US-6458779-B1 | TREATMENT OF CONDITIONS ASSOCIATED WITH EXCESS PRODUCTION OF SOLUBLE CD23 (S-CD23) SUCH AS AUTOIMMUNE DISEASE AND ALLERGY. THE COMPOUNDS OF THE INVENTION ARE ALSO INHIBITORS OF THE RELEASE OF TUMOUR NECROSIS FACTOR (TNF). | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-10-01 | — | — | US | claimed |
| US-20240239934-A1 | FUMARIC ACID DIESTER RESIN, FILM AND POLARIZING PLATE | TOSOH CORPORATION (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239934-A1 | FUMARIC ACID DIESTER RESIN, FILM AND POLARIZING PLATE | TOSOH CORPORATION (JP) | 2024-07-18 | — | — | US | disclosed |
| EP-4230619-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CELLIX BIO PRIVATE LIMITED (IN) | 2023-08-23 | — | — | EP | disclosed |
| EP-3481383-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | CELLIX BIO PRIVATE LTD (IN) | 2023-06-14 | — | — | EP | disclosed |
| EP-3402544-B1 | BIOCOMPATIBLE POLYSACCHARIDE HYDROGELS AND METHODS OF USAGE | SUN GUOMING (US) | 2022-12-07 | — | — | EP | disclosed |
| US-11399611-B2 | Process for straightening keratin fibres with a heating means and denaturing agents | L'OREAL (FR) | 2022-08-02 | — | — | US | disclosed |
| WO-2022109079-A1 | CONSUMER PRODUCT COMPRISING BIODEGRADABLE DELIVERY PARTICLES | THE PROCTER & GAMBLE COMPANY (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022109119-A1 | BIODEGRADABLE DELIVERY PARTICLES | ENCAPSYS, LLC (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2021129940-A1 | CURABLE PHOTOCHROMIC COMPOSITIONS INCLUDING AN OXAZOLINE FUNCTIONAL MATERIAL | TRANSITIONS OPTICAL, LTD. (IE) | 2021-07-01 | — | — | WO | disclosed |
| US-20100163070-A1 | METHOD FOR STRAIGHTENING KERATINOUS FIBRES USING HEATING MEANS AND AN AMIDE | L'OREAL S.A. (FR) | 2010-07-01 | — | — | US | disclosed |
| US-20100028280-A1 | PROCESS FOR STRAIGHTENING KERATIN FIBRES WITH A HEATING MEANS AND DENATURING AGENTS | L'OREAL S.A. (FR) | 2010-02-04 | — | — | US | disclosed |
| US-20090227621-A1 | Naphthyridine derivatives having inhibitory activity against hiv integrase | SHIONOGI & CO., LTD. (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090227621-A1 | Naphthyridine derivatives having inhibitory activity against hiv integrase | SHIONOGI & CO., LTD. (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090162762-A1 | ELECTROSTATIC IMAGE DEVELOPING TONER, PRODUCTION METHOD THEREOF, ELECTROSTATIC IMAGE DEVELOPER, IMAGE FORMING METHOD AND IMAGE FORMING APPARATUS | FUJI XEROX CO., LTD. (JP) | 2009-06-25 | — | — | US | disclosed |
| CN-101316585-A | Process for the stereoselective preparation of (-)-halofenate and intermediates thereof | METABOLEX INC (US) | 2008-12-03 | — | — | CN | disclosed |
| WO-2007107502-A1 | ADDITIVE FOR PRESERVING THE FLUIDITY OF FLUIDS CONTAINING GAS HYDRATES | AKZO NOBEL N.V. (NL) | 2007-09-27 | — | — | WO | disclosed |
| US-7226721-B2 | Underlayer coating forming composition for lithography containing compound having protected carboxyl group | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2007-06-05 | — | — | US | disclosed |
| US-4835312-A | Production process of N-substituted amide compounds | MITSUI CHEMICALS, INCORPORATED (JP) | 1989-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11399611-B2 | Process for straightening keratin fibres with a heating means and denaturing agents | KRT18, KRTCAP2, TUBB4A | MAPK1 1194/4885KDM4E 1460/4885HIF1A 2752/4885 |
| US-20100028280-A1 | PROCESS FOR STRAIGHTENING KERATIN FIBRES WITH A HEATING MEANS AND DENATURING AGENTS | KRT18, KRTCAP2, TUBB4A | MAPK1 1194/4885KDM4E 1460/4885HIF1A 2752/4885 |
| US-20090227621-A1 | Naphthyridine derivatives having inhibitory activity against hiv integrase | PNP, CDKL1, ASNS | MAPK1 2946/4885KDM4E 1068/4885HIF1A 4240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.